Paula Kareclas

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Hugo Ford, Andrea Marshall, John Bridgewater et al. · The Lancet Oncology · 2013 · 604 citations · Full text

Public Health, Community Health, Communities Of Practice +14

Protection of erythrocytes from human complement–mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy

Anita Hill, Simon H. Ridley, R G Oldroyd et al. · Blood · 2005 · 55 citations · Full text

Life Sciences, Hematology, Immunology +11

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial

Frank Waldron-Lynch, Paula Kareclas, Irons Kathryn et al. · BMJ Open · 2014 · 34 citations · Full text

Life Sciences, Immunology, Autoimmunity +15

COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.

Hugo Ford, Andrea Marshall, Jonathan Wadsley et al. · Journal of Clinical Oncology · 2013 · 32 citations

Medicine, Oncology, Pharmacology +12

A phase 2 study of vatalanib in metastatic melanoma patients

Natalie Cook, Bristi Basu, Swethajit Biswas et al. · European Journal of Cancer · 2010 · 25 citations

Medicine, Oncology, Pharmacology +14